es real-time polymerase chain reaction (PCR) to amplify, detect and measure minute levels of virus in blood samples as well as extremely high levels of these infectious agents. Real-time PCR enables the production of large quantities of DNA from very small samples in a short period of time, making it possible to detect extremely low levels of a virus's genetic material. The Abbott
m2000 system automates the important steps of the process, from sample preparation to data analysis, allowing laboratories to process molecular tests efficiently, accurately and confidently.
In addition to having a best-in-class assay for HIV-1, Abbott's m2000 system is faster than competitive systems, delivering 96 test results in less than six hours for HIV-1 as compared to up to two days for other systems.
About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available at the company's Web site at www.abbott.com.
'/>"/>Page: 1 2 3 Related medicine technology :1.
GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA2.
GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America3.
German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 20084.
Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General5.
Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees6.
Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations7.
NCPS Outraged at HIV/AIDS Medi-Cal Cuts8.
Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City9.
Test for Life Campaign Screens Record Number of DC Residents for HIV/AIDS10.
U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims11.
On World AIDS Day, CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV/AIDS